Workflow
Jasper Therapeutics Shares Fall On Briquilimab Drug Lot Problem

Core Viewpoint - Jasper Therapeutics, Inc. is facing a significant decline in stock price, dropping nearly 55% amid high trading volume, following the release of updated data from its BEACON study on briquilimab for chronic spontaneous urticaria (CSU) [1][10]. Group 1: Study Results - The BEACON Phase 1b/2a study reported briquilimab's safety, tolerability, and clinical activity, with primary endpoints focusing on these aspects [2]. - In the study, 89% of participants achieved a complete response, and 78% achieved a clinical response by week 2 [4]. - Mean changes in Urticaria Activity Score over 7 days (UAS7) showed reductions of 28.3 points in the 240mg cohort and 22.9 points in the 360mg cohort at 4 weeks [4]. Group 2: Ongoing Investigations and Adjustments - The company is investigating issues related to a specific drug product lot that affected results in certain cohorts, with findings expected in the coming weeks [6]. - Additional patient enrollment is planned to strengthen the data set for the Phase 2b CSU study, with results anticipated in Q4 2025 and study commencement expected in mid-2026 [7]. Group 3: Strategic Changes - To prioritize resources for briquilimab in CSU, the company is halting the asthma study and pausing development in severe combined immunodeficiency (SCID) [8]. - Cost-cutting measures, including potential restructuring, are being implemented to extend the company's financial runway [8].